Voclosporin is under clinical development by Aurinia Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Voclosporin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Voclosporin overview

Voclosporin (Lupkynis) is a novel cyclosporine analog and immunosuppressive agent. It is formulated as soft gelatin capsules for oral route of administration. Lupkynis is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). 
Voclosporin (ISA-247) is under development for the treatment of lupus nephritis (LN), minimal change disease (MCD), idiopathic nephrotic syndrome and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in kidney transplant recipients (KTRs). It is administered through the oral route as a capsule and ophthalmic route as solution. The drug candidate acts by targeting calcineurin. Voclosporin is developed by modification of the functional group on the amino acid residue at position 1 of the cyclosporin A (CsA) molecule.
It was also under development for lupus erythematosus, focal segmental glomerulosclerosis (FSGS) all proteinuric nephrology indications and prevention of ophthalmic indications like uveitis and dry eye syndrome and moderate to severe plaque psoriasis and prevention of organ rejection following renal transplantation.

Aurinia Pharmaceuticals overview

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company. Its pipeline product includes voclosporin, (lupkynis). Its lupkynis is an orally administered CNI immunosuppressant, to treat adult patients with active lupus nephritis. Aurinia Pharmaceuticals voclosporin is used in clinical studies in patients with psoriasis, kidney transplantation, uveitis and dry eye syndrome indications. It collaborates with Otsuka Pharmaceutical Co., Ltd for the development and commercialization of oral voclosporin. The company operates in Canada and the US. Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada.

For a complete picture of Voclosporin’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.